Palatin Technologies Inc PTN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $5.99
- Day Range
- $5.40–5.99
- 52-Week Range
- $5.40–31.00
- Bid/Ask
- $3.00 / $8.83
- Shares Outstanding
- 1.78M
- Market Cap
- $9.83M
- Volume/Avg
- 64,640 / 63,912
Key Statistics
- Price/Earnings (Normalized)
- 0.03
- Price/Sales
- 1.18
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system. Its product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. It is also developing, dependent on resources for development activities, MC1R agonist products, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It has one operating segment life science.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 25
- Website
- https://www.palatin.com
Valuation
|
Metric
|
PTN
|
|---|---|
Price/Earnings (Normalized) | 0.03 |
Price/Book Value | 1.47 |
Price/Sales | 1.18 |
Price/Cash Flow | — |
Price/Earnings
PTN
Financial Strength
|
Metric
|
PTN
|
|---|---|
Quick Ratio | 4.40 |
Current Ratio | 4.61 |
Interest Coverage | −1,244.60 |
Quick Ratio
PTN
Profitability
|
Metric
|
PTN
|
|---|---|
Return on Assets (Normalized) | −104.73% |
Return on Equity (Normalized) | −221.64% |
Return on Invested Capital (Normalized) | −211.47% |
Return on Assets
PTN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|@$cr$M$ | LOCK|!%H&& | $130B | |||
| Moderna Inc
MRNA
| LOCK|&mKG?> | LOCK|>x | $97B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|^kw#^S! | LOCK|kGR? | $83B | |||
| argenx SE ADR
ARGX
| LOCK|!J#nB>$ | LOCK|dm | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|tZW?&<t | LOCK|bh& | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|ysY<GF& | LOCK|y>GPr | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|N&@M%^<g | LOCK|s!vXn | $28B | |||
| Incyte Corp
INCY
| LOCK|rKqbzPt | LOCK|RJ | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|vPj$>r! | LOCK|C$ | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|QC!yTgW | LOCK|?y | $14B |
United States